




PHARMACEUTICAL 2020

RespireRx Pharmaceuticals Inc.
Rank 342 of 358





PHARMACEUTICAL 2020

RespireRx Pharmaceuticals Inc. Rank 342 of 358

The relative strengths and weaknesses of RespireRx Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of RespireRx Pharmaceuticals Inc. compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 320% points. The greatest weakness of RespireRx Pharmaceuticals Inc. is the variable Assets, Current, reducing the Economic Capital Ratio by 208% points.

The company's Economic Capital Ratio, given in the ranking table, is -396%, being 432% points below the market average of 36%.

Input Variable	Value in 1000 USD
Assets, Current	45
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	7,490
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	0
Other Expenses	405
Other Liabilities	0
Other Net Income	26
Other Revenues	0
Property and Equipment	0
Research and Development	599
Selling, General and Administrative Expense	1,137

Output Variable	Value in 1000 USD
Assets	45
Liabilities	7,490
Expenses	2,141
Revenues	0
Stockholders Equity	-7,445
Net Income	-2,115
Comprehensive Net Income	-2,115
Economic Capital Ratio	-396%